483
Novartis Pharmaceuticals CorporationFDA 483 - Novartis Pharmaceuticals Corporation - August 21, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Novartis Pharmaceuticals Corp. in East Hanover, NJ, revealed a failure to ensure proper monitoring of a clinical study. Specifically, investigational product was not stored at the required temperature and was dispensed to subjects, with monitoring visits failing to identify these temperature excursions. This indicates a critical lapse in clinical trial oversight and product integrity.
Open in Dashboard
ID · b86a870b-4f00-4ca2-a2ea-f19029e24813